You BETer be aware - learnings from a negative Phase 1 study

Oncotarget. 2019 May 7;10(34):3145-3146. doi: 10.18632/oncotarget.26898.

Authors

Sophie Postei-Vinoy^{1

2}, Matthias Ocker³

Affiliations

¹ Drug Development Department (DITEP), Gustave Roussy Cancer Campus, Paris-Saclay University, Villejuif, France.
² NSERM, UMR981, ATIP- Avenir Group,Villejuif, France.
³ Translational Medicine Oncology, Bayer AG, Berlin, Germany.

No abstract available

Keywords: BET inhibitor; Phase 1; epigenetics-3; modelling; tox.

Publication types

Editorial